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Osteoclasts are generated from monocyte/macrophage-lineage precursors in response to colony-stimulating factor 1 (CSF-1) and receptor activator of nuclear factor-κB ligand (RANKL) O steoclasts are bone-resorbing cells generated from monocyte/macrophage-lineage precursors. The differentiation of osteoclast precursors (OCPs) into osteoclasts is regulated by bone-forming osteoblasts. Osteoblastic cells express two cytokines responsible for osteoclastogenesis: one is colony-stimulating factor 1 [CSF-1, also called macrophage colony-stimulating factor (M-CSF)] and the other is receptor activator of nuclear factor-κB ligand (RANKL). OCPs express CSF-1 receptor (CSF-1R, also called c-Fms) and RANK (receptor for RANKL) and differentiate into osteoclasts in response to CSF-1 and RANKL. The expression of RANKL is up-regulated by osteoclast-inducing factors such as parathyroid hormone (PTH) and 1α,25-dihydroxyvitamin D 3 [1α,25(OH) 2 
D 3 ] (1, 2).
CSF-1 is the most potent growth factor for monocytes/macrophages (3), but its synthesis by osteoblasts occurs independently of PTH and 1α,25(OH) 2 D 3 (2) . CSF-1 op/op mice cannot produce a functionally active CSF-1 (4), and therefore, exhibit monocytopenia and osteopetrosis (OP) (5, 6 Fig. 2A) . Consistent with the previous report (14) , IL-34 was expressed predominantly in spleen but slightly in bone ( Fig. 2A) . The osteoblast level of IL-34 mRNA was much lower compared with that of CSF-1 mRNA (Fig. 2B) . Little IL-34 mRNA or CSF-1 mRNA was expressed in bone marrow (BM) macrophages and osteoclastic cells (Fig. 2B) . IL-34(+) cells were mainly distributed in the splenic red pulp region and marginal zones (Fig. 2C) , where RANK(+)/CSF-1R(+) cells were detected (Fig. 1B) . IL-34(+) cells were similarly distributed in the spleen in WT mice ( Fig. S1 A and B) . population was much lower in bone than in spleen, consistent with the result of real-time RT-PCR ( Fig. 2A) . These results suggest that IL-34 is involved in the generation of OCPs in spleen in CSF-1 op/op mice. Then, we examined the biological activities of IL-34 in several assays and found them to be similar to those of CSF-1 (Fig. S2) . Consistent with the previous reports (14-17), IL-34 promoted not only the proliferation of BM macrophages (Fig. S2A) , but also the formation of osteoclasts (Fig. S2B) , both of which were similarly inhibited by adding αCSF-1R Ab. IL-34 as well as CSF-1 supported the survival of osteoclasts, which was similarly inhibited by adding αCSF-1R Ab (Fig. S2C) . Thus, IL-34 is concluded to stimulate osteoclastogenesis through CSF-1R. These results suggest that splenic OCPs are transferred from spleen to bone in response to CSF-1/IL-34 administration in CSF-1 op/op mice. We then examined the effect of splenectomy (SPX) on osteoclast formation in CSF-1 op/op mice (Fig. 3A) . Three-week-old CSF-1 op/op mice were subjected to SPX or a sham operation (Sham) and injected with CSF-1 4 d after the surgery. The CSF-1 injection produced tartrate-resistant acid phosphatase (TRAP, an osteoclast marker)(+) osteoclasts in bone in Sham CSF-1 op/op mice, but not in SPX CSF-1 op/op mice. RANKL −/− mice were also subjected to SPX or Sham and examined for osteoclastogenesis in response to RANKL (Fig. 3B) . The RANKL injection produced osteoclasts in bone both in Sham and SPX RANKL −/− mice. RANKL appeared to induce osteoclasts to form from RANK (+)/CSF-1R(+) cells preexisting in bone in RANKL −/− mice. The administration of VEGF improved the phenotype of osteopetrosis in CSF-1 op/op mice (11, 12) , and a deficiency of VEGFR1 worsened it (12) . VEGF may stimulate the growth and IL-34 synthesis of vascular endothelial cells. Consistent with the previous reports (11, 12) , the injection of VEGF-A 120 (VEGF 120 ) into CSF-1 op/op mice increased the appearance of TRAP(+) osteoclasts (Fig. S3A ). SPX prevented VEGF-A 120 -induced osteoclastogenesis in CSF-1 op/op mice. However, the VEGF 120 injection did not increase the expression of IL-34 mRNA in bone, liver, or spleen in CSF-1 op/op mice (Fig. S3B ). These results suggest that VEGF induces loosening of the endothelial cell contacts (25) , and the subsequent entry of OCPs into the blood stream.
We (Fig. 4) . TRAP(+) osteoclasts were detected in bone in 10-wk-old and 10-mo-old CSF-1 op/op mice (Fig. 4A) . The expression of IL-34 mRNA in bone and spleen but not in the liver increased with aging in CSF-1 op/op mice (Fig. 4B) . WT mice also exhibited an age-associated increase in IL-34 expression in bone. CSF-1 mRNA expression showed no correlation with aging in WT mice (Fig. 4B) . Then, 5-wk-old CSF-1 op/op mice were subjected to SPX or Sham. Five weeks later, tibiae were recovered and examined for osteoclastogenesis (Fig. 4C) . Histomorphometric analysis of tibiae showed that SPX suppressed the age-associated appearance of osteoclasts, erosion surface/bone surface (ES/BS), and increased bone volume/tissue volume (BV/TV) in aged CSF-1 op/op mice (Fig. 4C) . These results suggest that spleen acts as a reservoir of OCPs in the age-associated appearance of osteoclasts in CSF-1 op/op mice. We previously reported that a large amount of a 2MD analog, 2-methyl-2MD, induced hypercalcemia in WT mice, but not in cFos −/− mice (21). The potency of 2-methyl-2MD as well as 2MD in inducing osteoclastogenesis was 100 times higher than that of 1α,25(OH) 2 D 3 (21) . In the course of investigating further, we found that administration of 2-methyl-2MD to CSF-1 op/op mice induced hypercalcemia (Fig. S4) . We, then, examined whether administration of the original 2MD induces osteoclastogenesis in CSF-1 op/op mice. CSF-1 op/op mice subjected to SPX or Sham were injected with a large amount of 2MD (Fig. 5A) . The 2MD injection induced the appearance of TRAP(+) osteoclasts in bone in Sham but not in SPX CSF-1 op/op mice. 2MD increased erosion surface in parallel with the increase of osteoclast number in Sham but not in SPX CSF-1 op/op mice (Fig. 5A ). 2MD is known to induce RANKL expression in osteoblastic cells (20, 21) . Then, RANKL was injected into CSF-1 op/op mice, but neither the osteoclast formation nor the increase in erosion surface (ES/BS) was observed (Fig. 5A) . The administration of 2MD stimulated the expression of IL-34 mRNA in spleen and bone in CSF-1 op/op mice (Fig. 5B) . The number of IL-34(+)/PECAM-1(+) cells and that of RANK(+)/CSF-1R(+) cells were also increased in response to 2MD administration ( Fig. 5 C and D) . We then performed siRNA-mediated knockdown of IL-34. Using fluorescence-labeled control siRNA, we confirmed that the siRNA was successfully delivered to spleen and bone (Fig. S5A) . Then IL-34 siRNA or control siRNA was injected into CSF-1 op/op mice 24 h before the administration of 2MD. The expression of IL-34 mRNA in spleen was reduced by up to 80% by adding IL-34 siRNA (Fig. S5B) . IL-34 siRNA but not control siRNA suppressed the 2MD-induced osteoclastogenesis in CSF-1 op/op mice (Fig. 5E ). These results indicate that IL-34 is involved in the 2MD-induced mobilization of OCPs from spleen to bone in CSF-1 op/op mice. We finally examined whether 2MD-induced upregulation of IL-34 expression is mediated by the vitamin D receptor (VDR) using VDR −/− mice. Although comparable levels of IL-34 mRNA expression were detected in bone and spleen in VDR −/− mice, the IL-34 expression was not enhanced by 2MD administration (Fig. 5F ).
Discussion
We have shown that spleen in CSF-1 op/op mice acts as a reservoir of OCPs, which are transferred to bone and differentiate into osteoclasts in response to diverse stimuli (Fig. 6) . The existence of OCPs in spleen seems to be supported by IL-34 expressed in vascular endothelial cells. The mysterious phenomena observed in CSF-1 op/op mice (7-12) may be explained by the transfer of OCPs from spleen to bone.
The exclusive localization of OCPs in spleen was observed in CSF-1 op/op mice but not in RANKL −/− mice. SPX prevented osteoclastogenesis in 2MD-induced osteoclastogenesis in CSF-1 op/op mice. However, 2MD-induced osteoclastogenesis in normal mice was not impaired by SPX (Fig. S6) . Therefore, it is unlikely that spleen acts as a reservoir of OCPs in osteoclastogenesis under the physiological condition in normal animals. However, 2MD administration increased the number of OCPs as mice, we demonstrated that OCPs existed in the peripheral blood as well as in bone marrow (26) . Circulating OCPs were cell-cycle-arrested cells committed to the osteoclast lineage. When CSF-1 was injected into CSF-1 op/op mice, osteoclasts detected in bone were generated from cell-cycle-arrested OCPs (18) . Our findings also support the notion that the lineagecommitted OCPs circulate in the blood stream and fix to the correct site for osteoclastogenesis. Ishii et al. (27) reported that an agonist of sphingosine 1 phosphate (S1P) increased the migration of OCPs between blood and bone. CSF-1 administration increased the mobilization of OCPs from spleen to bone, suggesting that CSF-1 as well as IL-34 plays important roles not only in the osteoclastic differentiation of OCPs in bone but also in the mobilization of OCPs from spleen to bone in CSF-1 op/op mice. Future studies will further clarify the mechanism by which OCPs are transferred from spleen into blood and home to bone.
The expression level of IL-34 was much lower in bone than in spleen. This may explain why OCPs and osteoclasts are absent in bone in young CSF-1 op/op mice. Osteoclasts appeared in aged CSF-1 op/op mice with concomitant up-regulation of IL-34 expression in bone. 2MD administration also enhanced IL-34 expression in bone. These results suggest that IL-34 generated by vascular endothelial cells contributes to osteoclastogenesis induced by aging and 2MD administration in CSF-1 op/op mice. VEGF also induced osteoclastogenesis in CSF-1 op/op mice. However, the ability of VEGF to induce osteoclastogenesis was much weaker than that of CSF-1 and 2MD, and VEGF failed to up-regulate IL-34 expression. These results suggest that IL-34 expressed in vascular endothelial cells in bone is essentially involved in osteoclastogenesis in CSF-1 op/op mice. Administration of 2MD induced osteoclastogenesis with upregulation of IL-34 expression in CSF-1 op/op mice. The RNA interference experiment further supported the notion that IL-34 is involved in the 2MD-induced osteoclastogenesis in CSF-1 op/op mice. When 2MD was administered to WT mice, the expression of IL-34 mRNA was significantly increased in WT mice (Fig. S7) . The stimulatory effect of 2MD on IL-34 expression was not observed in VDR −/− mice. Administration of a large amount of 1α,25(OH) 2 D 3 into CSF-1 op/op mice also induced osteoclastogenesis (Fig. S8) . These findings suggest that the IL-34 gene is a unique target of 1α,25(OH) 2 mice and WT mice at various ages. Data were obtained from triplicate PCRs using RNA from three mice and expressed as the mean ± SD. (C) Effect of splenectomy on age-associated osteoclastogenesis. Five-week-old CSF-1 op/op mice were subjected to SPX or Sham. Five weeks later, they were killed. Sections of tibiae were double stained for TRAP and methyl green (Left). Osteoclast number (number/mm), erosion surface/bone surface (ES/BS, %), and bone volume/tissue volume, (BV/TV, %) were measured (Right). Data are expressed as the mean ± SD for four optical fields from four mice. (Scale bar, 50 μm.) *P < 0.01. NS, not significant.
We have not succeeded in showing the stimulation of IL-34 expression by 2MD in mouse splenic endothelial cell cultures. Vascular microenvironment or blood vascular networks may be required for 2MD-induced up-regulation of IL-34 expression. Vascular endothelial cells are shown to regulate the recruitment of monocyte/macrophage lineage cells, which play a role in angiogenesis (28) (29) (30) (31) . At the amino acid sequence level, IL-34 gene is more conserved than the CSF-1 gene during evolution (32) . These results suggest that the vitamin D system and IL-34 may fundamentally work in normal angiogenesis.
Recently, it was reported that IL-34 was expressed in synovial tissues obtained from rheumatoid arthritis patients, and tumor necrosis factor α (TNFα) stimulated IL-34 expression in those synovial fibroblasts in culture (33, 34) . Giant cell tumors of bone have been shown to express IL-34 (17) . Therefore, we examined the effects of osteotropic factors such as 1α,25(OH) 2 D 3 , 2MD, TNFα, interleukin 1β (IL-1β) and prostaglandin E 2 (PGE 2 ) on IL-34 expression in mouse osteoblastic cells in culture (Fig. S9) . Real-time RT-PCR analysis showed that TNFα, IL-1β, and PGE 2 , respectively, failed to increase IL-34 mRNA expression in osteoblastic cells in our cell culture conditions. 2MD and 1α,25 (OH) 2 D 3 significantly increased IL-34 mRNA expression in osteoblastic cells. However, it is unlikely that IL-34 expressed by osteoblastic cells in response to 1α,25(OH) 2 D 3 can substitute for CSF-1 for osteoclastogenesis, because 1α,25(OH) 2 D 3 failed to support osteoclast formation in cocultures of hematopoietic osteoclast precursors and CSF-1 op/op mouse-derived osteoblastic cells (35) . At present, the cause of the difference between our result and the results reported previously is not known. Further studies will elucidate the regulatory mechanism of IL-34 expression in fibroblastic cells as well as endothelial cells.
Both CSF-1 op/op and RANKL −/− osteopetrotic mice develop splenic extramedullary hematopoiesis due to the impaired bone microenvironment. This suggests that spleen acts as the reservoir of hematopoietic precursors under pathological conditions such as osteopetrosis. Recently, Miyamoto et al. (36) reported that the mobilization of hematopoietic stem and progenitor cells (HSPCs) occurring after granulocyte colony-stimulating factor (G-CSF) injection was comparable or even increased in osteopetrotic CSF-1 op/op , RANKL −/− and c-Fos −/− mice, compared with that in WT mice. Contrary to OCPs, the mobilization of HSPCs was not suppressed by SPX in CSF-1 op/op mice in the G-CSF treatment (36) . These results suggest that spleen cannot act as the reservoir of HSPCs in CSF-1 op/op mice, although HSPCs exist in the enlarged spleen. Swirski et al. (37) identified unique monocytes in spleen, which exited the spleen en masse, accumulated in the injured tissue, and participated in wound healing, in response to ischemic myocardial injury. CSF-1 has been shown to be involved in the coordinated dynamics of the tissue distribution of macrophages and dendritic cells (38) . Thus, spleen plays important roles in the maintenance and tissue distribution of monocyte-macrophage lineage cells through IL-34 expression.
In vitamin D. Clarifying how splenic OCPs enter the blood stream and reach bone may provide a unique strategy to control bone resorption.
Materials and Methods
Detailed protocols are given in SI Materials and Methods.
Animals. Breeding pairs of CSF-1 op /+ mice (B6C3Fe genetic background) were purchased from The Jackson Laboratory and F 2 mice were raised in our laboratory. Homozygous CSF-1 op/op mice, identified by a lack of incisors at postnatal day 10, and RANKL −/− mice (39) (C57BL/6 background) were fed a softened rodent chow (Oriental Yeast) with water after weaning. VDR −/− mice (C57BL/6 background) were generated by cross-breeding of VDR-floxed mice with CMV-Cre mice (40) . VDR −/− mice were fed a high calcium diet (CE-2 supplemented with 2% (wt/wt) calcium, 1.25% (wt/wt) phosphate, and 20% (wt/wt) lactose; CLEA Japan) to normalize serum calcium level. Eight-weekold male ddY mice and newborn ddY mice (Japan SLC) were used as WT mice for preparation of BM cells and osteoblastic cells, respectively. All experiments were conducted in accordance with the guidelines for studies with laboratory animals of the Matsumoto Dental University Experimental Animal Committee.
Splenectomy. Mice were anesthetized with isoflurane (Isoflu; Dainippon Sumitomo Pharma) using a vaporizer (DS Pharma Biomedical). The spleen was identified after a transverse laparotomy incision just to the left of the spinal cord and removed after appropriate blood vessel ligation. Sham-operated animals underwent the laparotomy without a splenectomy.
Statistics. Statistical analyses were performed using the one-tailed Student t test and Fisher's exact probability test, as appropriate. P < 0.05 was considered statistically significant.
